All-cause mortality

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Access to an NNRTI-based ART program more than halved mortality among a cohort of HIV-infected women who had previously received single-dose nevirapine for PMTCT, with the reduction remaining signific

Effect: improvement; RH = 0.46; CI: 95% CI: 0.23-0.91

Aortic stenosis was significantly associated with increased all-cause mortality in MI patients treated with DAPT, with approximately 2-fold increased risk in Sweden and 1.5-fold in Denmark.

Effect: decline; HR 1.76; CI: 95% CI 1.26-2.47

Aortic stenosis was significantly associated with increased all-cause mortality in MI patients treated with DAPT, with approximately 2-fold increased risk in Sweden and 1.5-fold in Denmark.

Effect: decline; HR 1.76; CI: 95% CI 1.26-2.47

Aortic stenosis was significantly associated with increased all-cause mortality in MI patients treated with DAPT, with approximately 2-fold increased risk in Sweden and 1.5-fold in Denmark.

Effect: decline; HR 1.76; CI: 95% CI 1.26-2.47

Aortic stenosis was significantly associated with increased all-cause mortality in MI patients treated with DAPT, with approximately 2-fold increased risk in Sweden and 1.5-fold in Denmark.

Effect: decline; HR 1.76; CI: 95% CI 1.26-2.47

Aortic stenosis was significantly associated with increased all-cause mortality in MI patients treated with DAPT, with approximately 2-fold increased risk in Sweden and 1.5-fold in Denmark.

Effect: decline; HR 1.76; CI: 95% CI 1.26-2.47

Aortic stenosis was significantly associated with increased all-cause mortality in MI patients treated with DAPT, with approximately 2-fold increased risk in Sweden and 1.5-fold in Denmark.

Effect: decline; HR 1.76; CI: 95% CI 1.26-2.47

Aortic stenosis was significantly associated with increased all-cause mortality in MI patients treated with DAPT, with approximately 2-fold increased risk in Sweden and 1.5-fold in Denmark.

Effect: decline; HR 1.76; CI: 95% CI 1.26-2.47

Aortic stenosis was significantly associated with increased all-cause mortality in MI patients treated with DAPT, with approximately 2-fold increased risk in Sweden and 1.5-fold in Denmark.

Effect: decline; HR 1.76; CI: 95% CI 1.26-2.47

Aortic stenosis was significantly associated with increased all-cause mortality in MI patients treated with DAPT, with approximately 2-fold increased risk in Sweden and 1.5-fold in Denmark.

Effect: decline; HR 1.76; CI: 95% CI 1.26-2.47

Aortic stenosis was significantly associated with increased all-cause mortality in MI patients treated with DAPT, with approximately 2-fold increased risk in Sweden and 1.5-fold in Denmark.

Effect: decline; HR 1.76; CI: 95% CI 1.26-2.47

Aortic stenosis was significantly associated with increased all-cause mortality in MI patients treated with DAPT, with approximately 2-fold increased risk in Sweden and 1.5-fold in Denmark.

Effect: decline; HR 1.76; CI: 95% CI 1.26-2.47

Aortic stenosis was significantly associated with increased all-cause mortality in MI patients treated with DAPT, with approximately 2-fold increased risk in Sweden and 1.5-fold in Denmark.

Effect: decline; HR 1.76; CI: 95% CI 1.26-2.47

Aortic stenosis was significantly associated with increased all-cause mortality in MI patients treated with DAPT, with approximately 2-fold increased risk in Sweden and 1.5-fold in Denmark.

Effect: decline; HR 1.76; CI: 95% CI 1.26-2.47

Aortic stenosis was significantly associated with increased all-cause mortality in MI patients treated with DAPT, with approximately 2-fold increased risk in Sweden and 1.5-fold in Denmark.

Effect: decline; HR 1.76; CI: 95% CI 1.26-2.47

Aortic stenosis was significantly associated with increased all-cause mortality in MI patients treated with DAPT, with approximately 2-fold increased risk in Sweden and 1.5-fold in Denmark.

Effect: decline; HR 1.76; CI: 95% CI 1.26-2.47

Aortic stenosis was significantly associated with increased all-cause mortality in MI patients treated with DAPT, with approximately 2-fold increased risk in Sweden and 1.5-fold in Denmark.

Effect: decline; HR 1.76; CI: 95% CI 1.26-2.47

Aortic stenosis was significantly associated with increased all-cause mortality in MI patients treated with DAPT, with approximately 2-fold increased risk in Sweden and 1.5-fold in Denmark.

Effect: decline; HR 1.76; CI: 95% CI 1.26-2.47

Aortic stenosis was significantly associated with increased all-cause mortality in MI patients treated with DAPT, with approximately 2-fold increased risk in Sweden and 1.5-fold in Denmark.

Effect: decline; HR 1.76; CI: 95% CI 1.26-2.47

Aortic stenosis was significantly associated with increased all-cause mortality in MI patients treated with DAPT, with approximately 2-fold increased risk in Sweden and 1.5-fold in Denmark.

Effect: decline; HR 1.76; CI: 95% CI 1.26-2.47

Aortic stenosis was significantly associated with increased all-cause mortality in MI patients treated with DAPT, with approximately 2-fold increased risk in Sweden and 1.5-fold in Denmark.

Effect: decline; HR 1.76; CI: 95% CI 1.26-2.47

Aortic stenosis was significantly associated with increased all-cause mortality in MI patients treated with DAPT, with approximately 2-fold increased risk in Sweden and 1.5-fold in Denmark.

Effect: decline; HR 1.76; CI: 95% CI 1.26-2.47

Aortic stenosis was significantly associated with increased all-cause mortality in MI patients treated with DAPT, with approximately 2-fold increased risk in Sweden and 1.5-fold in Denmark.

Effect: decline; HR 1.76; CI: 95% CI 1.26-2.47

Aortic stenosis was significantly associated with increased all-cause mortality in MI patients treated with DAPT, with approximately 2-fold increased risk in Sweden and 1.5-fold in Denmark.

Effect: decline; HR 1.76; CI: 95% CI 1.26-2.47